The INNOCENT project is divided into seven work packages, covering the scientific and technical aspects of the project, exploitation and dissemination of results, ethic requirements and project management.
WP1. Synthesis of nanocarrier
This WP is devoted to the synthesis and characterization of organic nanomaterials (for targeted delivery of therapeutic agents and plasmid) and inorganic nanocrystals (for MRI imaging and therapy).
WP2. Detailed characterisation of synthesized nanomaterial
The results obtained in this WP will allow us to assess the putative effects of physico-chemical properties on key biological processes.
WP3 Safe by design: Hazard and risk assessment of the nanocarrier
The toxic potential of the novel multimodal nanodrug will be investigated at all development stages, through an integrated approach.
W4 Drug treatment in vitro
We will study the efficiency of single as well as combined targeted treatment on non-adherent 3D cultures. Mutual cooperation chemotherapy, epigenetic treatment and gene therapy will be assessed.
WP5 Drug treatment in vivo
Efficacy of targeted therapy will be evaluated on orthotopic as well as metastatic in vivo model at cellular and molecular level.
WP6 OMICS - Expression, Epigenome, Processing, Data analysis
OMICS analyses will be applied to confirm that combined demethylation therapy is sufficient to reverse hypermethylation-induced gene silencing of tumour suppressor and other cancer-related genes.
WP7. Consortium management, communication, decision making, data processing, and dissemination
Each work package will be managed by a work package leader who will be responsible for the timely delivery of deliverables to the Coordinator, who in turn represents the Consortium to the Commission.